Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Univariate and multivariate Cox regression analysis of the gene signature and survival of NSCLC patients in TCGA cohort

From: A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer

Variables Group Patients
(N)
Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
DFS
 Age ≤ 67/> 67 383/378 0.97 (0.75–1.26) 8.30E−01 1.11 (0.85–1.45) 4.30E−01
 Gender Female/male 326/435 0.96 (0.74–1.25) 7.60E−01 1.08 (0.81–1.43) 6.00E−01
 Stage I/II 410/220 1.64 (1.21–2.22) 1.30E−03 1.74 (1.28–2.37) 3.60E−04
 Stage I/III 410/109 2.16 (1.51–3.08) 2.20E−05 2.25 (1.57–3.22) 9.30E−06
 Stage I/IV 410/22 1.76 (0.82–3.80) 1.50E−01 1.56 (0.71–3.40) 2.70E−01
 Histological type Adeno/squamous 395/366 0.65 (0.50–0.85) 1.60E−03 0.58 (0.43–0.77) 1.60E−04
 Risk score Low/high 380/381 1.33 (1.02–1.73) 3.70E−02 1.40 (1.08–1.83) 1.30E−02
OS
 Age ≤ 67/> 67 383/378 1.25 (0.98–1.58) 7.10E−02 1.34 (1.05–1.70) 1.90E−02
 Gender Female/male 326/435 1.22 (0.96–1.57) 1.10E−01 1.19 (0.92–1.53) 2.00E−01
 Stage I/II 410/220 1.51 (1.14–2.00) 4.30E−03 1.45 (1.09–1.93) 1.10E−02
 Stage I/III 410/109 2.07 (1.50–2.85) 9.60E−06 2.04 (1.47–2.83) 1.80E−05
 Stage I/IV 410/22 2.77 (1.59–4.83) 3.20E−04 2.83 (1.60–5.00) 3.40E−04
 Histological type Adeno/squamous 395/366 1.13 (0.89–1.44) 3.20E−01 0.93 (0.71–1.22) 5.90E−01
 Risk score Low/high 380/381 1.54 (1.20–1.96) 5.50E−04 1.48 (1.14–1.91) 3.30E−03
  1. HR: hazard ratio; CI: confidence interval; Adeno: adenocarcinoma; Squamous: squamous cell carcinoma